Clinical Trial Update: Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating liposomal doxorubicin and etoposide in recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Doxil (liposomal doxorubicin) (liposomal doxorubicin)
• Etoposide (Etoposide)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 1 | Status: TERMINATED